Current therapies for multiple sclerosis (MS) reduce both relapses and relapse-associated
worsening of disability, which is assumed to be mainly associated with transient infiltration of …

Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic
signaling that is critical for proliferation and survival of leukemic cells in many B cell …

B cell receptor (BCR) signalling is crucial for normal B cell development and adaptive
immunity. BCR signalling also supports the survival and growth of malignant B cells in …

Background The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in
few durable remissions. Bruton's tyrosine kinase (BTK), an essential component of B-cell …

Ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase, is an effective therapy for
patients with chronic lymphocytic leukemia (CLL). To determine whether rituximab provides …

Background Chronic lymphocytic leukemia (CLL) primarily affects older persons who often
have coexisting conditions in addition to disease-related immunosuppression and …

Chronic Lymphocytic Leukemia Treatment of CLL, the most common leukemia in the West,
has undergone a revolution in the past few years with the development of agents that target …

Bruton's tyrosine kinase (BTK) is a key component of B cell receptor (BCR) signalling and
functions as an important regulator of cell proliferation and cell survival in various B cell …

Objective Fenebrutinib (GDC‐0853) is a noncovalent, oral, and highly selective inhibitor of
Bruton's tyrosine kinase (BTK). The efficacy, safety, and pharmacodynamics of fenebrutinib …

Bruton tyrosine kinase (BTK) is a nonreceptor tyrosine kinase that plays a central role in the
signal transduction of the B-cell antigen receptor and other cell surface receptors, both in …